Orgenesis, a global biotech company has secured a $5 million equity line of credit from Williamsburg Venture Holdings. The deal provides $750,000 upon registration effectiveness, with a further $4.25 million accessible over two years. The funding will support Orgenesis’ initiatives
Lyndra Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering long-acting oral therapies, has announced the appointment of Adam Sayer as its new President and Chief Executive Officer. Sayer, who also joins the company’s Board of Directors, succeeds Jessica Ballinger, the
miRecule, a biotechnology company developing RNA-based therapies, has announced a new strategic partnership with GBI Biomanufacturing, a contract development and manufacturing organisation (CDMO), to accelerate the development and clinical supply of its innovative Antibody-RNA Conjugate (ARC) therapies. The collaboration aims to
Amgen celebrated the official opening of its state-of-the-art drug substance manufacturing facility in Holly Springs, North Carolina, on January 24. The event, which featured a ribbon-cutting ceremony, marked the first phase of the company’s $1.5 billion investment in the region.
Alvotech, a global biotech company focused on biosimilars, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration (FDA) has accepted their Biologics License Applications (BLAs) for AVT05. The proposed biosimilar
Ascentage Pharma, a China-based biotechnology firm, raised $126 million in its US initial public offering (IPO), marking the first biotech IPO of 2025. The company sold 7,325,000 American Depositary Shares (ADS) at $17.25 each. Trading began on 24 January on
AbbVie has entered into a collaboration and option-to-license agreement with Neomorph, Inc. to advance the development of molecular glue degraders for oncology and immunology. The partnership aims to tackle challenging and historically “undruggable” protein targets by leveraging molecular glue degraders—a
Disc Medicine, Inc., a clinical-stage biopharmaceutical company, has announced the pricing of its upsized underwritten public offering. The offering includes 3,918,182 shares of common stock priced at $55.00 per share and pre-funded warrants for 181,818 shares priced at $54.9999 per
Bioxytran, Inc., a clinical-stage biotechnology company focusing on therapies for viral diseases and fibrotic conditions, has announced a $1.6 million common stock purchase agreement with TRITON FUNDS LP. The funds will be used to pay down existing debt, advance pre-clinical
Polyrizon, a biotech company focused on innovative intranasal hydrogels, has announced the commencement of Good Manufacturing Practice (GMP) manufacturing preparations for its PL-14 allergy blocker. This milestone is a critical step in readiness for the company’s planned 2025 clinical trial.
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups Sign up for our weekly newsletter
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
